睿知中国医院研究地图
候选清单

福州福建医科大学

福建医科大学附属第一医院

First Affiliated Hospital of Fujian Medical University

在本站收录的 53 种疾病中,这家医院列在其中 26 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

福建医科大学附属第一医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma17 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma3 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma59 篇牵头论文
  4. 胃癌Stomach cancer38 篇牵头论文牵头 1 项开放试验
  5. 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
  6. 骨肉瘤Osteosarcoma13 篇牵头论文
  7. 胃肠道间质瘤Gastrointestinal stromal tumour2 篇牵头论文
  8. 神经母细胞瘤Neuroblastoma5 篇牵头论文
  9. 多发性骨髓瘤Multiple myeloma15 篇牵头论文牵头 1 项开放试验
  10. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia0 篇牵头论文牵头 1 项开放试验
  11. β 地中海贫血Beta thalassaemia0 篇牵头论文
  12. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder4 篇牵头论文
  13. 重症肌无力Myasthenia gravis2 篇牵头论文
  14. 肝豆状核变性Wilson disease3 篇牵头论文牵头 1 项开放试验
  15. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis2 篇牵头论文
  16. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  17. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis6 篇牵头论文牵头 1 项开放试验
  18. 脊髓性肌萎缩症Spinal muscular atrophy0 篇牵头论文牵头 1 项开放试验
  19. 杜氏肌营养不良Duchenne muscular dystrophy5 篇牵头论文牵头 1 项开放试验
  20. 白塞病Behçet disease2 篇牵头论文
  21. IgA 肾病IgA nephropathy3 篇牵头论文
  22. 原发性胆汁性胆管炎Primary biliary cholangitis2 篇牵头论文
  23. 原发性硬化性胆管炎Primary sclerosing cholangitis2 篇牵头论文
  24. 先天性巨结肠Hirschsprung disease2 篇牵头论文
  25. 遗传性血管性水肿Hereditary angioedema0 篇牵头论文
  26. 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文

未列出的收录疾病:肝母细胞瘤、脊索瘤、尤文肉瘤、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、IgG4相关性疾病、烟雾病、胆道闭锁、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、法布雷病、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、遗传性大疱性表皮松解症、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 17 篇,占 0.7%。

牵头论文
17
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 2220222023: 3320232024: 5520242025: 442025

福州有 5 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题放疗技术影像与人工智能诱导/同步化疗
论文中的科室放疗科耳鼻喉/头颈外科影像/核医学科肿瘤内科
牵头的论文17
  1. LncRNA ZNF295-AS1 modulates nasopharyngeal carcinoma progression via the miR-762/HDAC6 axis-mediated autophagy.2025Cellular signalling
  2. Deformable registration for nasopharyngeal carcinoma using adaptive mask and weight allocation strategy based CycleFCNs model.2025Radiation oncology (London, England)免费全文
  3. Long-term trends in the burden of nasopharyngeal carcinoma in China: A comprehensive analysis from 1990 to 2021 and projections to 2030 based on the global burden of disease study 2021.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  4. VMAT with CCC Algorithm Optimizes Trismus Prevention: Dose-Response Analysis of Jaw Muscles Dmean and Dmax in T3-T4 Nasopharyngeal Carcinoma.2025Technology in cancer research & treatment免费全文
  5. Radiation-induced nasopharyngeal ulcers after re-irradiation with intensity-modulated radiotherapy in locoregional recurrent nasopharyngeal carcinoma patients: a dose-volume-outcome analysis.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  6. A head-to-head comparison of [68Ga]Ga-DOTATATE and [68Ga]Ga-FAPI PET/CT in patients with nasopharyngeal carcinoma: a single-center, prospective study.2024European journal of nuclear medicine and molecular imaging
  7. Polo-like kinase 1 inhibitor NMS-P937 represses nasopharyngeal carcinoma progression via induction of mitotic abnormalities.2024Journal of biochemical and molecular toxicology
  8. The association analysis between fatigue and body composition loss in patients with nasopharyngeal carcinoma during radiotherapy: An observational longitudinal study.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  9. Curcumin derivative C210 induces Epstein-Barr virus lytic cycle and inhibits virion production by disrupting Hsp90 function.2024Scientific reports免费全文
  10. The effect of early oral nutritional supplements on improving nutritional outcomes and radiation-induced oral mucositis for nasopharyngeal carcinoma patients undergoing concurrent chemoradiotherapy.2023Head & neck
  11. Effect of nutritional status before radiotherapy on radiation-induced acute toxicities in patients with nasopharyngeal carcinoma.2023Head & neck
  12. Correlation between hippocampal radiation doses and psychological condition for patients with stage T1-2 nasopharyngeal carcinoma.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  13. The psychological status in patients with nasopharyngeal carcinoma during radiotherapy.2022European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  14. [68Ga]Ga-FAPI PET/CT Improves the T Staging of Patients with Newly Diagnosed Nasopharyngeal Carcinoma: A Comparison with [18F]F-FDG.2022Molecular imaging and biology
  15. Prognostic models for 1-year survival of NPC after radiotherapy in different ages.2021European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  16. Anxiety and depression status prior to radiotherapy in patients with nasopharyngeal carcinoma and its effect on acute radiation toxicities.2021European journal of cancer care
  17. The effect of psychological condition before radiotherapy on prognosis in 390 patients initially treated for nasopharyngeal carcinoma.2021Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study已完成NCT05990998牵头方I/II期2022-11 启动
  2. Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic Images状态不明NCT05627310研究中心2022-11 启动
  3. Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma已完成NCT04823468研究中心不分期2021-07 启动
  4. Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma状态不明NCT02944708研究中心III期2015-10 启动
PubMed 以外找到的论文(未计入)6
  1. LBA103 Early versus routine oral nutritional supplements during concurrent chemoradiotherapy for nasopharyngeal carcinoma: Efficacy and cost-utility analysis in a multicenter randomized controlled trial2025Annals of Oncology会议摘要
  2. Multicenter dosimetric consistency evaluation of IMRT and VMAT techniques based on AAPM TG119 Report and clinical cases2025Radiation Medicine and Protection论文
  3. Signal “off-on” electrochemical aptamer sensing of interleukin-6 based on platinum nanoparticles/MIL-88B MOF nanozyme2025Talanta Open论文
  4. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.2025Journal of Clinical Oncology会议摘要
  5. Identifying immune cell infiltration and diagnostic biomarkers for nasopharyngeal carcinoma through bioinformatic analysis2024Research Square预印本
  6. General Introduction of PET/CT of Nasopharyngeal Carcinoma2023Springer eBooks书籍章节

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 222025

福州有 5 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    分期
    III期
    开始
    2025-03
    登记号
    NCT06644781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫治疗
论文中的科室肿瘤内科
牵头的论文3
  1. Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China.2025Expert review of pharmacoeconomics & outcomes research
  2. First-line toripalimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma: A cost-effectiveness analysis.2025PloS one免费全文
  3. LncRNA NRON negatively regulates cisplatin-induced cell apoptosis via downregulating miR-31 in esophageal squamous cell carcinomas.2022In vitro cellular & developmental biology. Animal
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)正在招募NCT06644781研究中心III期2025-03 启动
  2. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma已终止NCT05461794研究中心II期2022-10 启动
  3. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  4. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
  5. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
PubMed 以外找到的论文(未计入)11
  1. CircSLC7A5 upregulates NRD1 by competing with miR-148a-3p to promote progression of esophageal squamous cell carcinoma2025Research Square预印本
  2. Agaricus blazei murrill and Enteromorpha prolifera-derived polysaccharides gain therapeutic effects on esophageal squamous cell carcinoma2024Journal of Functional Foods论文
  3. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  4. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  5. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  6. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  7. Targeting UNC-51-like kinase 1 can inhibit esophageal cancer cell proliferation and regulate autophagy2023Research Square预印本
  8. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figshare数据集
  9. Association between tea consumption and quality of life in men with esophageal squamous carcinoma based on TTD model2022Research Square预印本
  10. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figshare数据集
  11. Real-world clinical effectiveness and safety of camrelizumab in esophageal squamous cell carcinoma.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 59 篇,占 0.4%。

牵头论文
59
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 9920222023: 7720232024: 131320242025: 23232025

福州有 6 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
    分期
    I期
    开始
    2025-08
    登记号
    NCT07391839

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心上海、南京、合肥、广州、杭州、济南、福州、郑州

  2. 正在招募
    Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
    分期
    未注明
    开始
    2024-08
    登记号
    NCT06561399

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建省立医院;另有 2 家列出的医院为研究中心福州

  3. 正在招募
    Neoadjuvant Triple Therapy for Resectable HCC
    分期
    未注明
    开始
    2024-09
    登记号
    NCT06569498

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建省立医院;另有 4 家列出的医院为研究中心厦门、福州

  4. 正在招募
    Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
    分期
    未注明
    开始
    2024-09
    登记号
    NCT06602011

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建省立医院;另有 4 家列出的医院为研究中心厦门、福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现乙肝与肝硬化
论文中的科室影像/核医学科病理/检验科普外/肝胆胰外科肿瘤内科
牵头的论文59
  1. Epigenetic Silencing of SFRP5 Promotes Hepatocellular Carcinoma Progression and Metastasis via Wnt/β-Catenin Signaling.2025APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  2. Decision Fusion Model for Predicting Microvascular Invasion in Hepatocellular Carcinoma Based on Multi-MR Habitat Imaging and Machine-Learning Classifiers.2025Academic radiology
  3. Percutaneous MR-Guided Thermal Ablation for Recurrent Subcentimeter Hepatocellular Carcinoma.2025Academic radiology
  4. Predicting Microvascular Invasion and Early Recurrence in Hepatocellular Carcinoma Using DeepLab V3+ Segmentation of Multiregional MR Habitat Images.2025Academic radiology
  5. Single-cell and bulk transcriptome analysis unveils a ligand-receptor-based signature for prognostication and reveals that TREM1 controls the malignant behaviors of hepatocellular carcinoma.2025Acta biochimica et biophysica Sinica免费全文
  6. Lenvatinib combined with anti-PD-1 antibodies plus locoregional treatment for initial unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter real-world study.2025BMC cancer免费全文
  7. Refining MR-guided thermal ablation for HCC within the Milan criteria: a decade of clinical outcomes and predictive modeling at a single institution.2025BMC cancer免费全文
  8. HRAS Induces Ferroptosis through Upregulating HSPB1 in Hepatocellular Carcinoma.2025Combinatorial chemistry & high throughput screening
  9. CDK4 as a Prognostic Marker of Hepatocellular Carcinoma and CDK4 Inhibitors as Potential Therapeutics.2025Current medicinal chemistry免费全文
  10. Intratumoral Microbe Correlated with Expression of DNA Methylation Genes in Hepatocellular Carcinoma.2025Digestive diseases and sciences免费全文
  11. E2F2/MUC1 Enhances Cell Stemness of Hepatocellular Carcinoma by Regulating the Notch Signaling Pathway.2025Digestive diseases and sciences
  12. Tumor suppressor OSR1 is modified by SUMO1 and regulates the Wnt/β-catenin signaling pathway in HCC.2025Experimental cell research
  13. Utilization of artificial circular RNAs as miRNA sponges and anti-PD-1 scFv expression platforms to suppress hepatocellular carcinoma progression.2025Frontiers in immunology免费全文
  14. The diagnostic value of hepatitis B core-related antigen in occult hepatitis B virus infection and its related hepatocellular carcinoma.2025International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  15. Predictive Value of Peripheral Blood Follicular Helper T Cells for Short-term Prognosis in Patients with Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors.2025Iranian journal of allergy, asthma, and immunology
  16. An analysis of the clinical efficacy and safety of a temperature-sensitive liquid embolic agent loaded with lobaplatin for the treatment of unresectable primary hepatocellular carcinoma through chemoembolization.2025Journal of cancer research and therapeutics
  17. The Efficacy and Safety of TACE or HAIC Combined With ICIs and Angiogenesis Inhibitors in Unresectable Hepatocellular Carcinoma.2025Journal of immunotherapy (Hagerstown, Md. : 1997)
  18. A Nomogram Based on MRI Visual Decision Tree to Evaluate Vascular Endothelial Growth Factor in Hepatocellular Carcinoma.2025Journal of magnetic resonance imaging : JMRI免费全文
  19. A CCR5 antagonist enhances the radiosensitivity of hepatocarcinoma in a mouse model.2025Journal of radiation research免费全文
  20. MR-Guided Microwave Ablation for Patients with Cirrhosis Complicated by Small Hepatocellular Carcinoma.2025Journal of vascular and interventional radiology : JVIR
  21. Computed tomography radiomics prediction of survival in hepatocellular carcinoma and is associated with ADH1A expression of the retinol metabolism pathway.2025Medicine免费全文
  22. Construction and validation of a novel model for guiding targeted combined immunotherapy in advanced hepatocellular carcinoma.2025Scientific reports免费全文
  23. Machine learning analysis identified NNMT as a potential therapeutic target for hepatocellular carcinoma based on PCD-related genes.2025Scientific reports免费全文
  24. Delta-radiomics Analysis Based on Multi-phase Contrast-enhanced MRI to Predict Early Recurrence in Hepatocellular Carcinoma After Percutaneous Thermal Ablation.2024Academic radiology
  25. Prognostic value of FDX1, the cuprotosis key gene, and its prediction models across imaging modalities and histology.2024BMC cancer免费全文
  26. A novel super-enhancer-related risk model for predicting prognosis and guiding personalized treatment in hepatocellular carcinoma.2024BMC cancer免费全文
  27. Efficacy of immune checkpoint inhibitors differs in various status of carcinoma: a study based on 29 cohorts with 3255 participants.2024Cancer immunology, immunotherapy : CII免费全文
  28. Long non-coding RNAFOXD1-AS1 modulated CTCs epithelial-mesenchymal transition and immune escape in hepatocellular carcinoma in vitro by sponging miR-615-3p.2024Cancer reports (Hoboken, N.J.)免费全文
  29. Detection of serum large and middle hepatitis B virus surface proteins: A novel potential diagnostic and prognostic biomarker for chronic hepatitis B.2024Clinica chimica acta; international journal of clinical chemistry
  30. ARHGEF39 targeted by E2F1 fosters hepatocellular carcinoma metastasis by mediating fatty acid metabolism.2024Clinics and research in hepatology and gastroenterology
  31. Monocyte distribution width as a promising biomarker for differential diagnosis of chronic hepatitis, cirrhosis, and hepatocellular carcinoma.2024Frontiers in immunology免费全文
  32. Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2024Journal of clinical pharmacology
  33. Clinical-Radiologic Morphology-Radiomics Model on Gadobenate Dimeglumine-Enhanced MRI for Identification of Highly Aggressive Hepatocellular Carcinoma: Temporal Validation and Multiscanner Validation.2024Journal of magnetic resonance imaging : JMRI
  34. The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study.2024Scientific reports免费全文
  35. Novel nomograms based on microvascular invasion grade for early-stage hepatocellular carcinoma after curative hepatectomy.2024Scientific reports免费全文
  36. Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma.2024World journal of surgical oncology免费全文
  37. LI-RADS category 3, 4, and M observations: a multiple parameters diagnostic model for hepatocellular carcinoma.2023Acta radiologica (Stockholm, Sweden : 1987)
  38. Prognostic implications of alpha-fetoprotein and C-reactive protein elevation in hepatocellular carcinoma following resection (PACE): a large cohort study of 2770 patients.2023BMC cancer免费全文
  39. Emerging roles of bile acids in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.2023Cellular & molecular immunology免费全文
  40. The effect of adjuvant transarterial chemoembolization for hepatocellular carcinoma after liver resection based on risk stratification.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  41. The impact of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with hepatocellular carcinoma after radical resection.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  42. Development and validation of a diagnostic model for AFP-negative hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  43. ATP13A2 is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  44. Added-value of ancillary imaging features for differentiating hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma on Gd-BOPTA-enhanced MRI in LI-RADS M.2022Abdominal radiology (New York)
  45. Deubiquitinating enzyme JOSD2 promotes hepatocellular carcinoma progression through interacting with and inhibiting CTNNB1 degradation.2022Cell biology international
  46. Compartmentalisation of Hepatitis B virus X gene evolution in hepatocellular carcinoma microenvironment and the genotype-phenotype correlation of tumorigenicity in HBV-related patients with hepatocellular carcinoma.2022Emerging microbes & infections免费全文
  47. Adenosine Triphosphate in Serum as a Promising Biomarker for Differential Diagnosis of Hepatitis B Disease Progression.2022Frontiers in immunology免费全文
  48. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.2022Journal of cancer research and clinical oncology免费全文
  49. Emerging role of mitochondria in response to HBV infection.2022Journal of clinical laboratory analysis免费全文
  50. A simplified model for prophylactic transarterial chemoembolization after resection for patients with hepatocellular carcinoma.2022PloS one免费全文
  51. Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.2022The Australasian journal of dermatology
  52. Radiomic analysis based on multi-phase magnetic resonance imaging to predict preoperatively microvascular invasion in hepatocellular carcinoma.2022World journal of gastroenterology免费全文
  53. A radiomics nomogram based on contrast-enhanced MRI for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma.2021Abdominal radiology (New York)
  54. Tumor Microenvironment Triggered Cascade-Activation Nanoplatform for Synergistic and Precise Treatment of Hepatocellular Carcinoma.2021Advanced healthcare materials
  55. FAM83G promotes proliferation, invasion, and metastasis by regulating PI3K/AKT signaling in hepatocellular carcinoma cells.2021Biochemical and biophysical research communications
  56. IL-17 and IL-21 polymorphisms in relation to HBV related hepatocellular carcinoma in Chinese Han population.2021Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
  57. Development of pre and post-operative nomograms to predict individual survival for ideal liver resection candidates with hepatocellular carcinoma.2021Liver international : official journal of the International Association for the Study of the Liver
  58. [Retracted] Anticancer and apoptotic activities of oleanolic acid are mediated through cell cycle arrest and disruption of mitochondrial membrane potential in HepG2 human hepatocellular carcinoma cells.2021Molecular medicine reports免费全文
  59. Downregulation of triggering receptor expressed on myeloid cells 1 inhibits invasion and migration of liver cancer cells by mediating macrophage polarization.2021Oncology reports
中文论文(未计入)2
  1. [Research progress of long-chain non-coding RNA in lipid metabolism reprogramming in primary hepatocellular carcinoma].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [Research progress of non-coding RNA-encoding polypeptides in primary hepatocellular carcinoma].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
  1. A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC状态不明NCT06003673牵头方IV期2023-07 启动
  2. MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.正在招募NCT07391839研究中心I期2025-08 启动
  3. Neoadjuvant Triple Therapy for Resectable HCC正在招募NCT06569498研究中心2024-09 启动
  4. Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)正在招募NCT06561399研究中心2024-08 启动
  5. Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)正在招募NCT06602011研究中心2024-09 启动
  6. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere进行中,不再招募NCT06900543研究中心III期2025-04 启动
  7. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  8. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)已终止NCT04246177研究中心III期2020-05 启动
  9. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  10. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer已终止NCT04520906研究中心不分期2020-12 启动
  11. Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge状态不明NCT03277716研究中心不分期2017-12 启动
  12. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)已完成NCT00617981研究中心III期2008-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 38 篇,占 0.4%。

牵头论文
38
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 3320222023: 101020232024: 101020242025: 772025

福州有 5 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
    分期
    II期
    开始
    2024-06
    登记号
    NCT06791083

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学附属第一医院福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题手术影像与人工智能腹膜转移与晚期
论文中的科室消化/肝病科影像/核医学科肿瘤内科病理/检验科
牵头的论文38
  1. Deciphering the Risk of Developing Lung Cancer after the Diagnosis of Gastric Cancer with Genetic Evidence: A European and East Asian Populations-Based Mendelian Randomization Analysis.2026Cancer research and treatment免费全文
  2. Short-term and long-term efficacy of laparoscopic D2 lymphadenectomy combined with complete mesogastrium excision for locally advanced upper gastric cancer.2026Surgery
  3. Comparative efficacy of neoadjuvant imatinib therapy in gastric versus rectal gastrointestinal stromal tumors: a two-center retrospective cohort study.2025BMC gastroenterology免费全文
  4. Dual-layer spectral detector CT-based scoring system for noninvasive TP53 expression assessment and adjuvant chemotherapy response prediction in gastric cancer: a multicenter cross-sectional study.2025International journal of surgery (London, England)免费全文
  5. Taichunamide-A Inhibits Stomach Cancer Growth Through AKT/MAPK Pathway Suppression and EGFR Inhibitor Synergy.2025Journal of biochemical and molecular toxicology
  6. Novel m5C-dependent post-transcriptional regulation of KIF11 drives lymphatic metastasis in gastric cancer.2025Scientific reports免费全文
  7. YY1-mediated transcriptional regulation of LINC01615 inhibits WNT2 mRNA degradation to promote gastric cancer progression.2025Scientific reports免费全文
  8. PPM1B degradation mediated by TRIM25 ubiquitination modulates cell cycle and promotes gastric cancer growth.2025Scientific reports免费全文
  9. New classification of gastric polyps: An in-depth analysis and critical evaluation.2025World journal of gastroenterology免费全文
  10. ASO Author Reflections: A Multicenter Retrospective Study on the Clinical and Prognostic Value of Tumor Deposits in Advanced Gastric Cancer.2024Annals of surgical oncology
  11. Correlation Analysis Between Tumor Deposit and Clinicopathologic Characteristics and Prognosis of Gastric Cancer: A Multicenter Retrospective Study.2024Annals of surgical oncology
  12. The effect of supplementary parenteral nutrition with different energy intakes on clinical outcomes of patients after gastric cancer surgery.2024BMC surgery免费全文
  13. Modulation of YBX1-mediated PANoptosis inhibition by PPM1B and USP10 confers chemoresistance to oxaliplatin in gastric cancer.2024Cancer letters
  14. NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression.2024Cancer research
  15. Comments on "Novel strategy of hold-and-drag clip closure with mantis-like claw for post-gastric endoscopic submucosal dissection defect of <30 mm".2024Endoscopy
  16. Bioinformatics Analysis Reveals Prognostic Significance of the Macrophage Marker Gene Signature in Gastric Adenocarcinoma.2024Frontiers in bioscience (Landmark edition)
  17. The cost-effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.2024Pharmacogenomics免费全文
  18. Curcumin derivative C210 induces Epstein-Barr virus lytic cycle and inhibits virion production by disrupting Hsp90 function.2024Scientific reports免费全文
  19. Super-enhancer-driven ZFP36L1 promotes PD-L1 expression in infiltrative gastric cancer.2024eLife免费全文
  20. Integrated bioinformatics analysis for conducting a prognostic model and identifying immunotherapeutic targets in gastric cancer.2023BMC bioinformatics免费全文
  21. Evaluation of vital genes correlated with CD8 + T cell infiltration as prognostic biomarkers in stomach adenocarcinoma.2023BMC gastroenterology免费全文
  22. Sex-specific disparities of serum pepsinogen I in relation to body mass index.2023Clinical chemistry and laboratory medicine
  23. Impact of PIWIL1 Single Nucleotide Polymorphisms on Gastric Cancer Risk in a Chinese Population.2023Genetic testing and molecular biomarkers
  24. Association of Malnutrition Diagnosed Using Global Leadership Initiative on Malnutrition Criteria with Severe Postoperative Complications After Gastrectomy in Patients with Gastric Cancer.2023Journal of laparoendoscopic & advanced surgical techniques. Part A
  25. Pretreatment controlling nutritional status (CONUT) score and carcinoembryonic antigen level provide tumor progression and prognostic information in gastric cancer: A retrospective study.2023Medicine免费全文
  26. The short- and long-term effect of laparoscopic total gastrectomy in D2 radical treatment combined with spleno-pancreatectomy under membrane anatomy.2023Surgical endoscopy
  27. The short- and long-term effect of membrane anatomy-guided laparoscopic D2 lymphadenectomy plus regional complete mesogastrium excision for locally advanced gastric cancer.2023Surgical endoscopy
  28. Short and Long-term Efficacy of 3-dimensional Laparoscopic-assisted D2 Radical Gastrectomy Under the Guidance of Membrane Anatomy for Locally Advanced Gastric Cancer.2023Surgical laparoscopy, endoscopy & percutaneous techniques
  29. Transcriptome sequencing and miRNA-mRNA network construction in exosome of macrophage M2 in stomach adenocarcinoma.2023World journal of surgical oncology免费全文
  30. Prognostic value of long-term antidiabetic and antihypertensive therapy in postoperative gastric cancer patients: the FIESTA study.2022BMC gastroenterology免费全文
  31. The effects of nutritional support team intervention on postoperative immune function, nutritional statuses, inflammatory responses, clinical outcomes of elderly patients with gastric cancer.2022BMC surgery免费全文
  32. [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F]FDG PET/CT.2022European journal of nuclear medicine and molecular imaging
  33. Transcription factor KLF15 inhibits the proliferation and migration of gastric cancer cells via regulating the TFAP2A-AS1/NISCH axis.2021Biology direct免费全文
  34. Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  35. Widespread Metastatic Gastric Signet-Ring Cell Carcinoma Shown by 68Ga-FAPI PET/CT.2021Clinical nuclear medicine
  36. Genetic variants of autophagy-related genes in the PI3K/Akt/mTOR pathway and risk of gastric cancer in the Chinese population.2021Gene
  37. Sulfasalazine, a potent suppressor of gastric cancer proliferation and metastasis by inhibition of xCT: Conventional drug in new use.2021Journal of cellular and molecular medicine免费全文
  38. Effect of single-incision laparoscopic distal gastrectomy guided by ERAS and the influence on immune function.2021World journal of surgical oncology免费全文
中文论文(未计入)1
  1. [FTO mRNA expression level in gastric cancer tissues and its relationship with clinicopathological parameters and prognosis].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer正在招募NCT06791083牵头方II期2024-06 启动
  2. A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China已完成NCT06585501研究中心2024-08 启动
  3. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  4. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  5. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

福州有 3 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 13 篇,占 0.6%。

牵头论文
13
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 2220222023: 0020232024: 0020242025: 332025

福州有 9 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文13
  1. Licochalcone B targets neural cell adhesion molecule 1 to inhibit osteosarcoma progression and ferroptosis resistance via extracellular signal-regulated kinase 5 and nuclear factor kappa B pathways.2026Phytomedicine : international journal of phytotherapy and phytopharmacology
  2. The integrin α2-osteoclast axis: a key driver of bone destruction and therapeutic target in osteosarcoma.2025Journal of translational medicine
  3. Guggulsterone suppresses osteosarcoma progression by inhibiting glycolysis through MAPK signaling pathway.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  4. Brusatol inhibits malignant phenotypes and lipid metabolism of osteosarcoma cells by regulating PI3K/AKT and MAPK pathways.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  5. Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis.2022International journal of nanomedicine
  6. Generation and characterization of patient-derived xenografts from patients with osteosarcoma.2022Tissue & cell
  7. Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway.2021Acta biochimica et biophysica Sinica
  8. Epidermal growth factor receptor promotes tumor progression and contributes to gemcitabine resistance in osteosarcoma.2021Acta biochimica et biophysica Sinica
  9. KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma.2021Biochemical and biophysical research communications
  10. MicroRNA-1287-5p promotes ferroptosis of osteosarcoma cells through inhibiting GPX4.2021Free radical research
  11. Inhibition of BUB1 suppresses tumorigenesis of osteosarcoma via blocking of PI3K/Akt and ERK pathways.2021Journal of cellular and molecular medicine
  12. Prognostic role of the recepteur d'origine nantais (RON) expression in primary high-grade osteosarcoma.2021Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  13. Clinicopathological and prognostic value of NADPH oxidase 2 (NOX2) in primary osteosarcoma.2021Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
中文论文(未计入)2
  1. [Reconstruction of bone defects after resection of osteosarcoma in children with artificial hemi-knee prosthesis].2025Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  2. [Bioinformatics analysis of differently expressed genes in osteoblastic sarcoma and screening of key genes].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
早期论文(2016–2020 年)12
  1. HER4 promotes the growth and metastasis of osteosarcoma via the PI3K/AKT pathway.2020Acta biochimica et biophysica Sinica
  2. Long non-coding RNA LINC00426 contributes to doxorubicin resistance by sponging miR-4319 in osteosarcoma.2020Biology direct
  3. Synthesis and Application of a Long-Circulating Radiolabeled Peptide for Targeting of Osteosarcoma.2020Molecular imaging and biology
  4. ACTN4 Promotes the Proliferation, Migration, Metastasis of Osteosarcoma and Enhances its Invasive Ability through the NF-κB Pathway.2020Pathology oncology research : POR
  5. [Treatment and influencing factors of infection after limb salvage surgery for malignant tumor around knee joint].2020Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  6. A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro.2019International journal of nanomedicine
  7. Clinicopathological and prognostic values of ErbB receptor family amplification in primary osteosarcoma.2019Scandinavian journal of clinical and laboratory investigation
  8. Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma.2019World journal of surgical oncology
  9. miR-219a-5p represses migration and invasion of osteosarcoma cells via targeting EYA2.2018Artificial cells, nanomedicine, and biotechnology
  10. Comparative proteomics of cancer stem cells in osteosarcoma using ultra-high-performance liquid chromatography and Orbitrap Fusion mass spectrometer.2018Talanta
  11. Transdifferentiation of human MNNG/HOS osteosarcoma cells into vascular endothelial cells in vitro and in vivo.2017Oncology reports
  12. Verification of TREX1 as a promising indicator of judging the prognosis of osteosarcoma.2016Journal of orthopaedic surgery and research

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

福州有 6 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.4%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 1120242025: 112025

福州有 7 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室儿科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 15 篇,占 0.9%。

牵头论文
15
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 4420232024: 5520242025: 332025

福州有 2 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
    分期
    早期I期
    开始
    2020-08
    登记号
    NCT04504526

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:福建医科大学附属第一医院福州

  2. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  3. 正在招募
    Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    I期
    开始
    2024-05
    登记号
    NCT06375044

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、南京、天津、广州、杭州、福州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层联合用药复发与耐药
论文中的科室影像/核医学科肿瘤内科眼科/神经眼科
牵头的论文15
  1. Global burden and trends of multiple myeloma attributable to high body mass index: a comprehensive analysis of the global burden of disease 2021 study with projections to 2040.2025BMC public health免费全文
  2. The value of multiparametric functional MRI histogram features in assessing multiple myeloma activity.2025European radiology
  3. B4GALT3 as a Key Glycosyltransferase Gene in Multiple Myeloma Progression: Insights From Bioinformatics, Machine Learning, and Experimental Validation.2025Molecular carcinogenesis
  4. Super-enhancer mediated upregulation of MYEOV suppresses ferroptosis in lung adenocarcinoma.2024Cancer letters
  5. NCX1/Ca2+ promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NFκB signaling pathway.2024Cell communication and signaling : CCS免费全文
  6. [68Ga]Pentixafor PET/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F]FDG PET/CT.2024European journal of nuclear medicine and molecular imaging
  7. Role of BACH1 in multiple myeloma.2024Hematology (Amsterdam, Netherlands)
  8. SSBP1 is a novel prognostic marker and promotes disease progression via p38MAPK signaling pathway in multiple myeloma.2024Molecular carcinogenesis
  9. Retrospective Analysis of the Expression of CD56 in Multiple Myeloma with Bone-Related Extramedullary Diseases.2023Annals of clinical and laboratory science
  10. Metformin attenuates multiple myeloma cell proliferation and encourages apoptosis by suppressing METTL3-mediated m6A methylation of THRAP3, RBM25, and USP4.2023Cell cycle (Georgetown, Tex.)免费全文
  11. NCX1 disturbs calcium homeostasis and promotes RANKL-induced osteoclast differentiation by regulating JNK/c-Fos/NFATc1 signaling pathway in multiple myeloma.2023Clinical and experimental medicine免费全文
  12. Nuclear Medicine Application of Pentixafor/Pentixather Targeting CXCR4 for Imaging and Therapy in Related Disease.2023Mini reviews in medicinal chemistry
  13. NBR2/miR-561-5p/DLC1 axis inhibited the development of multiple myeloma by activating the AMPK/mTOR pathway to repress glycolysis.2022Neoplasma
  14. Pathophysiological role of calcium channels and transporters in the multiple myeloma.2021Cell communication and signaling : CCS免费全文
  15. Regulatory role of DEPTOR‑mediated cellular autophagy and mitochondrial reactive oxygen species in angiogenesis in multiple myeloma.2021International journal of molecular medicine免费全文
中文论文(未计入)2
  1. [Correlation between Serum Interleukin-33, β2-Microglobulin Levels and DS Stage in Patients with Multiple Myeloma].2023Zhongguo shi yan xue ye xue za zhi
  2. [Effect of γδ T cells on the Proliferation, Apoptosis and Autophagy of Multiple Myeloma Cells].2022Zhongguo shi yan xue ye xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases正在招募NCT04504526牵头方早期I期2020-08 启动
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  3. Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT06375044研究中心I期2024-05 启动
  4. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide进行中,不再招募NCT06208150研究中心III期2024-01 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年没有牵头B 细胞急性淋巴细胞白血病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

福州有 2 家医院列在B 细胞急性淋巴细胞白血病下全国有 88 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia
    分期
    I期
    开始
    2026-05
    登记号
    NCT07491263

    年龄 14 岁 至 未注明(登记的条件)

    牵头:福建医科大学附属第一医院福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia即将招募NCT07491263牵头方(推断)I期2026-05 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年没有牵头β 地中海贫血的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

福州有 4 家医院列在β 地中海贫血下全国有 133 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.8%。

牵头论文
4
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 2220242025: 002025

福州有 1 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06413654

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断急性发作治疗
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

福州有 2 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题常规免疫治疗胸腺与胸腺切除
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝豆状核变性

Wilson disease

2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.5%。

牵头论文
3
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 1120242025: 002025

福州有 1 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Registered Cohort Study on Wilson's Disease
    分期
    未注明
    开始
    2019-07
    登记号
    NCT04012658

    年龄未注明(登记的条件)

    牵头:福建医科大学附属第一医院福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题遗传学(ATP7B)脑部与运动症状诊断与铜代谢检测
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

福州有 2 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

福州有 4 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室放疗科
牵头的论文1
  1. Multi-Omics Analysis Links Mitochondrial-Related Genes to Idiopathic Pulmonary Fibrosis and In Vivo Transcriptome Validation.2025Translational research : the journal of laboratory and clinical medicine

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.8%。

牵头论文
6
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 2220242025: 222025

福州有 4 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Registered Cohort Study on Amyotrophic Lateral Sclerosis
    分期
    未注明
    开始
    2019-07
    登记号
    NCT04008329

    年龄未注明(登记的条件)

    牵头:福建医科大学附属第一医院福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经内科
牵头的论文6
  1. Research advances in dysphagia animal models.2025Animal models and experimental medicine
  2. Biomarker profile of a Chinese ALS cohort: A comprehensive clinical-biomarkers-imaging analysis.2025Neurobiology of disease
  3. Detection of pTDP-43 via routine muscle biopsy: A promising diagnostic biomarker for amyotrophic lateral sclerosis.2024Brain pathology (Zurich, Switzerland)
  4. Alterations in nasal microbiota of patients with amyotrophic lateral sclerosis.2024Chinese medical journal
  5. Peak expiratory flow is a reliably household pulmonary function parameter correlates with disease severity and survival of patients with amyotrophic lateral sclerosis.2022BMC neurology
  6. Decreased serum creatinine levels predict short survival in amyotrophic lateral sclerosis.2021Annals of clinical and translational neurology
早期论文(2016–2020 年)4
  1. Promoting identification of amyotrophic lateral sclerosis based on label-free plasma spectroscopy.2020Annals of clinical and translational neurology
  2. Identification and functional analysis of novel mutations in the SOD1 gene in Chinese patients with amyotrophic lateral sclerosis.2019Amyotrophic lateral sclerosis & frontotemporal degeneration
  3. Prognostic analysis of amyotrophic lateral sclerosis based on clinical features and plasma surface-enhanced Raman spectroscopy.2019Journal of biophotonics
  4. High frequency of the TARDBP p.M337 V mutation among south-eastern Chinese patients with familial amyotrophic lateral sclerosis.2018BMC neurology
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Registered Cohort Study on Amyotrophic Lateral Sclerosis正在招募NCT04008329牵头方2019-07 启动
  2. An IIT Clinical Study to Evaluate the Safety and Efficacy of a Single Intrathecal Injection of RJK002 in Patients With ALS进行中,不再招募NCT06454682研究中心早期I期2023-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年没有牵头脊髓性肌萎缩症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

福州有 2 家医院列在脊髓性肌萎缩症下全国有 49 家医院列在脊髓性肌萎缩症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Registered Cohort Study on SMA
    分期
    未注明
    开始
    2019-07
    登记号
    NCT04010604

    年龄 1 周 至 70 岁(登记的条件)

    牵头:福建医科大学附属第一医院福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
早期论文(2016–2020 年)3
  1. Is there cervical spine muscle weakness in patients with Hirayama disease? A morphological study about cross-sectional areas of muscles on MRI.2020European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  2. A 34-Year-Old Female Patient with Hirayama Disease Complicated by Severe Spinal Cord Injury.2019World neurosurgery
  3. Anterior Cervical Surgery for the Treatment of Hirayama Disease.2019World neurosurgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Antisense Oligonucleotide for Spinal Muscular Atrophy状态不明NCT05187260牵头方2022-01 启动
  2. A Registered Cohort Study on SMA正在招募NCT04010604牵头方(推断)2019-07 启动
  3. Adult Spinal Muscular Atrophy (SMA) China Registry进行中,不再招募NCT05618379研究中心2023-01 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 5 篇,占 2.4%。

牵头论文
5
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 0020232024: 2220242025: 002025

福州有 3 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Registered Cohort Study on Duchenne Muscular Dystrophy
    分期
    未注明
    开始
    2019-07
    登记号
    NCT04012671

    年龄 2 岁 至 未注明(登记的条件)

    牵头:福建医科大学附属第一医院福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经内科

这些论文过半是实验室或动物研究。

牵头的论文5
  1. enOsCas12f1-mediated exon skipping for Duchenne muscular dystrophy therapy in humanized mouse model.2024Journal of genetics and genomics = Yi chuan xue bao
  2. Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model.2024Nature communications
  3. CRISPR/Cas9-based genome editing for the modification of multiple duplications that cause Duchenne muscular dystrophy.2022Gene therapy
  4. Generation and characterization of an induced pluripotent stem cell line (FJMUNi001-A) from a patient with Duchenne muscular dystrophy carrying c.4518 + 512 T > A variant in the DMD gene.2022Stem cell research
  5. Establishment of a human iPSC line XMDYYYi001-A from a patient with Becker muscular dystrophy harboring duplications of exons 2-19 in dystrophin gene.2021Stem cell research
早期论文(2016–2020 年)2
  1. Cryptic exon activation causes dystrophinopathy in two Chinese families.2020European journal of human genetics : EJHG
  2. Clinical and mutational characteristics of Duchenne muscular dystrophy patients based on a comprehensive database in South China.2017Neuromuscular disorders : NMD
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. A Registered Cohort Study on Duchenne Muscular Dystrophy正在招募NCT04012671牵头方(推断)2019-07 启动
  2. A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy已完成NCT03760029研究中心不分期2019-07 启动
  3. Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy已完成NCT03179631研究中心III期2017-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

福州有 3 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.4%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 222025

福州有 4 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

福州有 4 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.0%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

福州有 2 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

福州有 4 家医院列在先天性巨结肠下全国有 76 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科
牵头的论文2
  1. CHA-based microarray with Cas12a universal readout for multiple microRNA detection.2025Mikrochimica acta
  2. 10-year experience with single-site laparoscopic-assisted Soave operation for Hirschsprung disease.2025Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性血管性水肿

Hereditary angioedema

2021–2025 年没有牵头遗传性血管性水肿的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

福州有 1 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China已完成NCT06346899研究中心2024-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

福州有 3 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他相关研究

联系这家医院

出示给工作人员或司机的院名卡

福建医科大学附属第一医院

First Affiliated Hospital of Fujian Medical University

福州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Binhai Campus of the First Affiliated Hospital; First Affiliated Hospital of Xiamen University; Longyan First Affiliated Hospital of Fujian Medical University; Binhai Branch of the First Affiliated Hospital

提出更正下载数据